Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
July 31, 2002
Primary Completion Date
February 28, 2006
Conditions
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Interventions
DRUG
gemcitabine hydrochloride
DRUG
topotecan hydrochloride
Trial Locations (1)
98195
University of Washington School of Medicine, Seattle
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Fred Hutchinson Cancer Center
OTHER
NCT00217555 - Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Biotech Hunter | Biotech Hunter